Libang Biomedical

Xi'an Libang Pharmaceutical is a prominent Chinese healthcare group established in 1996, specializing in the development and production of generic finished dosage forms, high-value APIs, and innovative biopharmaceuticals. The company is recognized as the largest supplier of generic propofol in China and maintains a strong presence in anesthesia, cardiovascular health, and clinical nutrition. Through its R&D arm, Beijing Libang Biomedicine, the group is expanding into oncology with a focus on bispecific antibodies, including a blinatumomab biosimilar currently in clinical development. Libang operates several GMP-certified manufacturing sites and collaborates with global partners like Chime Biologics to advance its biologics pipeline. With a workforce of approximately 2,000 employees, the company integrates research, manufacturing, and commercialization to serve both domestic and international markets.